EVT-103
(Redirected from EVT 103)
| Clinical data | |
|---|---|
| Other names | ENS-103 |
| Routes of administration | By mouth |
| Drug class | NMDA receptor antagonist |
| Identifiers | |
| CAS Number | |
EVT-103, also known as ENS-103, is an experimental medication which originated from Roche and is under development by Evotec AG for the treatment of major depressive disorder.[1] It acts as an NMDA receptor subunit 2B (NR2B) antagonist.[1] As of November 2017, no recent reports of development for major depressive disorder have been identified.[1] The drug was developed as a follow-up compound to EVT-101.[2] The chemical structure of EVT-103 has not been released.[2]
See also
References
- ^ 1.0 1.1 1.2 "EVT 103". AdisInsight. Springer Nature Switzerland AG.
- ^ 2.0 2.1 Ruppa KB, King D, Olson RE (2012). "NMDA Antagonists of GluN2B Subtype and Modulators of GluN2A, GluN2C, and GluN2D Subtypes—Recent Results and Developments". Annual Reports in Medicinal Chemistry Volume 47. Vol. 47. pp. 89–103. doi:10.1016/B978-0-12-396492-2.00007-2. ISBN 9780123964922. ISSN 0065-7743.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
Categories:
- Short description with empty Wikidata description
- Orphaned articles from August 2023
- Articles with invalid date parameter in template
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Experimental antidepressants
- Drugs with undisclosed chemical structures
- Experimental drugs
- NMDA receptor antagonists
- Nervous system drug stubs